What is Coherus BioSciences Forward Dividend Yield %?
As of today (2024-04-25), the Forward Annual Dividend Yield of Coherus BioSciences is 0.00%.
As of today (2024-04-25), the Trailing Annual Dividend Yield of Coherus BioSciences is 0.00%.
CHRS's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.555 * Ranked among companies with meaningful Forward Dividend Yield % only.
Coherus BioSciences's Dividends per Share for the
three
months ended in Dec. 2023 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of Coherus BioSciences's Forward Dividend Yield %
For the Biotechnology subindustry, Coherus BioSciences's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus BioSciences's Forward Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus BioSciences's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Coherus BioSciences's Forward Dividend Yield % falls into.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Coherus BioSciences Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Coherus BioSciences's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Coherus BioSciences (Coherus BioSciences) Business Description
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHRS has been successfully added to your